Table 2. Results of the base-case analysis and probabilistic sensitivity analysis: Men.

Age group	Strategy	Mean cost (£)	Mean QALYs	Mean CV events	Incremental cost	Incremental QALYs	ICER (£ per QALY gained)	Probability of cost-effectiveness at £20,000/QALY	Polypill vs current practice
									ICER(£ per QALY gained)
40–49	Current practice	1,625	7.202	0.0956	0	0	-	0%
	Optimal guideline care	1,634	7.216	0.0822	8	0.014	604	41%
	Polypill	1,878	7.229	0.0683	244	0.014	18,057	59%	9,166
50–59	Current practice	2,008	6.740	0.1499	0	0	-	0%
	Optimal guideline care	2,013	6.765	0.1290	5	0.025	182	0%
	Polypill	2,136	6.784	0.1119	123	0.019	6,466	100%	2,897
60–69	Optimal guideline care	2,315	6.524	0.1714	0	0	-	0%
	Current practice	2,343	6.477	0.2064	28	-0.047	Dominated	0%
	Polypill	2,386	6.539	0.1592	71	0.015	4,791	100%	698
70–74	Optimal guideline care	2,429	5.916	0.1890	0	0	-	9%
	Current practice	2,457	5.853	0.2334	28	-0.063	Dominated	0%
	Polypill	2,459	5.922	0.1861	31	0.006	5,068	91%	33
	Optimal guideline care	2,320	4.782	0.1988	0	0	-	69%
	Polypill	2,327	4.781	0.2005	7	-0.001	Dominated	31%	Dominant
75+	Current practice	2,395	4.692	0.2564	68	-0.089	Dominated	0%